Your shopping cart is currently empty

MG-1102 is a first-in-class dual binder of monomeric tau and pre-miRNA-146a, exhibiting specific inhibition of miRNA146a with IC 50 values of 0.21 mM for double-labeled pre-miRNA146a and 0.36 mM for mono-labeled pre-miRNA146a. It interacts with tau monomers with a K d of 3.21 mM as determined by surface plasmon resonance (SPR), positioning it as a potential multi-target-directed ligand (MTDL) for Alzheimer's disease (AD) [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | MG-1102 is a first-in-class dual binder of monomeric tau and pre-miRNA-146a, exhibiting specific inhibition of miRNA146a with IC 50 values of 0.21 mM for double-labeled pre-miRNA146a and 0.36 mM for mono-labeled pre-miRNA146a. It interacts with tau monomers with a K d of 3.21 mM as determined by surface plasmon resonance (SPR), positioning it as a potential multi-target-directed ligand (MTDL) for Alzheimer's disease (AD) [1]. |
| Molecular Weight | 386.47 |
| Formula | C22H18N4OS |
| Cas No. | 2567913-75-9 |
| Smiles | C(C=1C(=NNC1)C2=CC3=C(C=C2)C=C(OC)C=C3)N4C(=CC=C4)C5=NC=CS5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.